HENDERSON, NV — (Marketwired) — 03/22/16 — (OTCQB: RXSF), a healthcare technology and medical device company that develops autonomous fingerprint security products, today announced that the Company will be presenting at the , which will be held at the Marriott Marquis in New York, NY on Thursday, March 31, 2016.
Lorraine Yarde, Rx Safes– Chief Executive Officer, is scheduled to deliver a presentation at 8:30 am EST. The Company will also be available for one-on-one meetings with conference attendees and institutional investors throughout the day.
“Rx Safes– participation in the conference is a valuable opportunity to introduce the company, our strategy and overall value proposition to the investment community. We remain committed to capitalize and structure the Company to meet the listing requirements for the Nasdaq Capital Markets,” commented Lorraine Yarde.
This unique forum connects executive management teams from companies with a market cap of less than $600 million with small and micro-cap institutional investors, equity research analysts, investment banking professionals, private equity professionals and select media to promote awareness amongst key stakeholders in the investment community. The conference will feature approximately 80 public companies with compelling stories that have yet to be fully discovered by the investment community, with past attendance exceeding 475 investors.
RX Safes, Inc. designs, develops, engineers, and markets fingerprint medical devices and security storage solutions for consumers and healthcare professionals to regulate and secure the use of controlled substances at the end user (patient and consumer) level using patented, autonomous fingerprint technology that offers greater security and tighter controls over controlled substances. The company–s innovative and unique biometric security products include biometric PCA infusion pump regulators (RxSafeDOSE), biometric needleless injectors (Rx MyDOSE) and a line of biometric security and storage products (Rx DrugSAFE product line) designed for hospitals, Emergency Service providers, professional healthcare workers, assisted living facilities, skilled nursing facilities, out-patient clinic, private physician offices, as well as consumers. It is estimated that more than 100 people die each day in the U.S. from misuse and unauthorized access to controlled substances with a social and economic price tag of over $600 billion. The Company is dedicated to providing comprehensive solutions to address the economic issues caused by drug diversion and unauthorized access to these medications, with products ranging from fingerprint medication safes, portable medical storage solutions, PCA pendants, Needle Free Injectors, locks and its revolutionary Rx SafeEHR product which is a portable HIPAA compliant electronic health record. The company works with OEMs to improve their legacy products by integrating its patented autonomous fingerprint technology, while innovating and producing its own products. For additional information please visit .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management–s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company–s business strategy. The Company–s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company–s ability to implement its long range business plan for various applications of its technology; the Company–s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company–s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company–s reports filed with the Securities and Exchange Commission.
Like us on Facebook at
Follow us on Twitter at
Keywords: JPM16, Sidoti, SOTU, Donald Trump, Bernie Sanders, President Obama, JP Morgan Healthcare Conference, Drugs, prescription drug abuse, medicine, drug diversion, healthcare, overdose, addiction, fingerprint, biometric, safe, security, technology, government, lockbox, McKesson, Cardinal Health, CVS, Walgreens, hospital, health system, medical equipment, FDA, CDC, DEA, methadone, oxycontin, lortab, hydroconone, zohydro, Zogenix, Purdue, King Pharmaceutical, heroin, doctor, pharmacist, biometric, marijuana, weed, painkillers, clinics, sober house, rehabilitation, OTC, patients, health network, nurses, clinicians, labs, smuggle, drug money, oxy, abuse, speed, crack, cocaine, pills, roofies, qualudes, prozac, morphine, ambulance, EMS, paramedics, ecstasy, LSD, high, stoned, drugged, pharmaceutical, pharmacy, narcotics, non-profit, not-for-profit, nonprofit, foundation, padlock, Master Lock, infusion pump, drug delivery
Investor Relations Contact:
Tram Bui
646-536-7035
You must be logged in to post a comment Login